Skip to main content
. 2015 Aug 18;6(31):32244–32256. doi: 10.18632/oncotarget.4993

Figure 4. Kaplan-Meier survival curves combining blood type and antibody response to the Forssman antigen (Fs).

Figure 4

A. Prostate cancer patients treated with PROSTVAC-VF (p = 0.003); B. Control patients (p = 0.35). Type B and O patients with antibody responses to the Forssman antigen (purple line) have improved survival in the PROSTVAC-VF arm but not the control arm.